One open‐label RCT studied the effect of the mTOR inhibitor sirolimus in the treatment of patients critically ill with influenza in ICU (Table 1).34 Thirty‐eight participants were enrolled in this study, 19 received 2mg sirolimus for 10 days (“experimental”), and 19 did not (“control”). Here, MTOR is linked to influenza.